AstraZeneca - Evolving strategies: Managing treatment of early stage and advanced lung cancers
Extensive-stage SCLC: Changing the paradigm with immune-oncology combinations
Date
22 Sep 2020Session
AstraZeneca - Evolving strategies: Managing treatment of early stage and advanced lung cancersPresenters
David SpigelAuthors
D.R. SpigelAuthor affiliations
- Medical Oncology, Sarah Cannon Research Institute, 37203 - Nashville/US
Resources
Resources from the same session
Welcome and Introduction
Presenter: David Spigel
Session: AstraZeneca - Evolving strategies: Managing treatment of early stage and advanced lung cancers
Resources:
Webcast
Unresectable stage III NSCLC: Clinical advances in the implementation of immuno-oncology therapy
Presenter: Johan Vansteenkiste
Session: AstraZeneca - Evolving strategies: Managing treatment of early stage and advanced lung cancers
Resources:
Webcast
Early stage EGFRm NSCLC: Targeted treatment options following complete surgical resection
Presenter: Tom John
Session: AstraZeneca - Evolving strategies: Managing treatment of early stage and advanced lung cancers
Resources:
Webcast
Locally advanced or metastatic EGFRm NSCLC: Targeted treatment options to improve outcomes in the first-line setting and beyond progression
Presenter: David Planchard
Session: AstraZeneca - Evolving strategies: Managing treatment of early stage and advanced lung cancers
Resources:
Webcast
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
-
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and can only be disabled by changing your browser preferences.